- Home
- XXII vs PCSA Comparison
XXII vs PCSA Comparison
Compare XXII & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- PCSA
- Stock Information
- Founded
- XXII 1998
- PCSA 2011
- Country
- XXII United States
- PCSA United States
- Employees
- XXII N/A
- PCSA N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- PCSA Health Care
- Exchange
- XXII Nasdaq
- PCSA Nasdaq
- Market Cap
- XXII 3.9M
- PCSA 4.3M
- IPO Year
- XXII N/A
- PCSA N/A
- Fundamental
- Price
- XXII $5.35
- PCSA $0.98
- Analyst Decision
- XXII
- PCSA Strong Buy
- Analyst Count
- XXII 0
- PCSA 2
- Target Price
- XXII N/A
- PCSA $5.00
- AVG Volume (30 Days)
- XXII 105.4K
- PCSA 911.9K
- Earning Date
- XXII 11-12-2024
- PCSA 10-30-2024
- Dividend Yield
- XXII N/A
- PCSA N/A
- EPS Growth
- XXII N/A
- PCSA N/A
- EPS
- XXII N/A
- PCSA N/A
- Revenue
- XXII $17,304,000.00
- PCSA N/A
- Revenue This Year
- XXII $56.94
- PCSA N/A
- Revenue Next Year
- XXII $2.98
- PCSA N/A
- P/E Ratio
- XXII N/A
- PCSA N/A
- Revenue Growth
- XXII N/A
- PCSA N/A
- 52 Week Low
- XXII $3.90
- PCSA $0.85
- 52 Week High
- XXII $581.85
- PCSA $10.76
- Technical
- Relative Strength Index (RSI)
- XXII 24.73
- PCSA 45.74
- Support Level
- XXII $3.90
- PCSA $1.13
- Resistance Level
- XXII $12.29
- PCSA $1.50
- Average True Range (ATR)
- XXII 1.15
- PCSA 0.14
- MACD
- XXII -0.53
- PCSA -0.00
- Stochastic Oscillator
- XXII 14.11
- PCSA 14.81
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).